Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Excellence Unveiled: Karsen Kitchen
In the sixth installment of Excellence Unveiled, listen to Karsen Kitchen, class of 2025, discuss her 20-minute journey aboard a Blue Origin rocket and her...
Sat Jul 12, 2025

Coker Arboretum provides tranquility, history
At the intersection of East Cameron Avenue and Raleigh Street lies the Coker Arboretum, a lush green escape from the rest of UNC’s bustling campus...
Thu Jul 10, 2025

UNC ranked No. 3 best value public university by Princeton Review
UNC-Chapel Hill is ranked the No. 3 best value public university in the nation in The Princeton Review’s list of Best Value Colleges for 2025,...
Wed Jul 9, 2025

Orange County Hit Hard by Tropical Storm Chantal
More than 10 inches of rain fell in a matter of hours and rivers and creeks surged. In Chapel Hill, Morgan Creek exceeded flood stage...
Tue Jul 8, 2025